![leena_menghaney_credit_msf_access_campaign-copy.jpg](/resources/images/archive/2017/november/leena_menghaney_credit_msf_access_campaign-copy.jpg/featureImage)
MSF drags Pfizer to court in India over patent on high-cost Gavi-funded vaccine
The medical humanitarian aid organisation Médecins Sans Frontières has taken the Indian Patent Office to court over a patent it recently granted to Pfizer for the pneumonia vaccine, Prevenar 13. MSF argues that the patent will stifle competition, blocking the development of cheaper, generic versions of the vaccine.